Salsalate-induced changes in lipid, Lipoprotein, and apoprotein concentrations in overweight or obese, insulin-resistant, nondiabetic individuals

被引:11
作者
Ariel, Danit [1 ]
Kim, Sun H. [1 ]
Liu, Alice [1 ]
Abbasi, Fahim [1 ]
Lamendola, Cindy A. [1 ]
Grove, Kaylene [1 ]
Tomasso, Vanessa [1 ]
Reaven, Gerald M. [1 ]
机构
[1] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA
基金
美国国家卫生研究院;
关键词
Lipid and/or lipoprotein abnormalities; Salsalate; Insulin resistance; Prediabetes; Cardiovascular disease risk; MEDIATED GLUCOSE-UPTAKE; RANDOMIZED-TRIAL; SUPPRESSION TEST; CARDIOVASCULAR-DISEASE; ASSOCIATION; RISK; CHOLESTEROL; CLAMP;
D O I
10.1016/j.jacl.2015.06.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND AND OBJECTIVE: Although salsalate administration consistently lowers plasma triglyceride concentrations in patients with type 11 diabetes, prediabetes, and/or insulin resistance, changes in low-density lipoprotein cholesterol (LDL-C) concentrations have been inconsistent; varying from no change to a significant increase. To evaluate the clinical relevance of this discordance in more detail, we directly measured LDL-C and obtained a comprehensive assessment of changes in lipid, lipoprotein, and apoprotein concentrations associated with salsalate use in insulin-resistant individuals, overweight or obese, but without diabetes, using vertical auto profile method. METHODS: A single-blind, randomized, placebo-controlled study was performed in volunteers who were overweight or obese, without diabetes, and insulin resistant on the basis of their steady-state plasma glucose concentration during an insulin suppression test. Participants were randomized 2:1 to receive salsalate 3.5 g/d (n = 27) or placebo (n = 14) for 4 weeks. Comprehensive lipid, lipoprotein, and apoprotein analysis by vertical auto profile was obtained after an overnight fast, before and after study intervention. RESULTS: There was no change in directly measured LDL-C concentration in salsalate-treated individuals. However, salsalate administration was associated with various changes considered to decrease atherogenicity; including decreases in triglyceride and total very low density lipoprotein cholesterol (VLDL-C) concentrations, a shift from small denser LDL lipoproteins toward larger, more buoyant LDL particles, decreases in VLDL1+2-C and LDL4-C, and nonsignificant decreases in non high-density lipoprotein cholesterol and apolipoprotein B. No significant changes occurred in the placebo-treated group. CONCLUSIONS: Atherogenicity of the lipid, lipoprotein, and apoprotein profile of insulin-resistant individuals who were overweight or obese improved significantly in association with salsalate treatment. The clinical importance of this finding awaits further study. (C) 2015 National Lipid Association. All rights reserved.
引用
收藏
页码:658 / 663
页数:6
相关论文
共 21 条
[1]   National Lipid Association Annual Summary of Clinical Lipidology 2015 [J].
Bays, Harold E. ;
Jones, Peter H. ;
Brown, W. Virgil ;
Jacobson, Terry A. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2014, 8 (06) :S1-S36
[2]   Multiple lipoprotein abnormalities associated with insulin resistance in healthy volunteers are identified by the vertical auto profile-II methodology [J].
Chu, JW ;
Abbasi, F ;
Kulkarni, KR ;
Lamendola, C ;
McLaughlin, TL ;
Scalisi, JN ;
Reaven, GM .
CLINICAL CHEMISTRY, 2003, 49 (06) :1014-1017
[3]   Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists [J].
Davidson, Michael H. ;
Ballantyne, Christie M. ;
Jacobson, Terry A. ;
Bittner, Vera A. ;
Braun, Lynne T. ;
Brown, Alan S. ;
Brown, W. Virgil ;
Cromwell, William C. ;
Goldberg, Ronald B. ;
McKenney, James M. ;
Remaley, Alan T. ;
Sniderman, Allan D. ;
Toth, Peter P. ;
Tsimikas, Sotirios ;
Ziajka, Paul E. ;
Maki, Kevin C. ;
Dicklin, Mary R. .
JOURNAL OF CLINICAL LIPIDOLOGY, 2011, 5 (05) :338-367
[4]   Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes [J].
Faghihimani, Elham ;
Aminorroaya, Ashraf ;
Rezvanian, Hassan ;
Adibi, Peyman ;
Ismail-Beigi, Faramarz ;
Amini, Masoud .
ACTA DIABETOLOGICA, 2013, 50 (04) :537-543
[5]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[6]   A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance [J].
Goldfine, A. B. ;
Conlin, P. R. ;
Halperin, F. ;
Koska, J. ;
Permana, P. ;
Schwenke, D. ;
Shoelson, S. E. ;
Reaven, P. D. .
DIABETOLOGIA, 2013, 56 (04) :714-723
[7]   Salicylate (Salsalate) in Patients With Type 2 Diabetes A Randomized Trial [J].
Goldfine, Allison B. ;
Fonseca, Vivian ;
Jablonski, Kathleen A. ;
Chen, Yii-Der Ida ;
Tipton, Laura ;
Staten, Myrlene A. ;
Shoelson, Steven E. .
ANNALS OF INTERNAL MEDICINE, 2013, 159 (01) :1-+
[8]   The Effects of Salsalate on Glycemic Control in Patients With Type 2 Diabetes A Randomized Trial [J].
Goldfine, Allison B. ;
Fonseca, Vivian ;
Jablonski, Kathleen A. ;
Pyle, Laura ;
Staten, Myrlene A. ;
Shoelson, Steven E. .
ANNALS OF INTERNAL MEDICINE, 2010, 152 (06) :346-+
[9]   ASSESSMENT OF INSULIN RESISTANCE WITH THE INSULIN SUPPRESSION TEST AND THE EUGLYCEMIC CLAMP [J].
GREENFIELD, MS ;
DOBERNE, L ;
KRAEMER, F ;
TOBEY, T ;
REAVEN, G .
DIABETES, 1981, 30 (05) :387-392
[10]   National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1-executive summary [J].
Jacobson, Terry A. ;
Ito, Matthew K. ;
Maki, Kevin C. ;
Orringer, Carl E. ;
Bays, Harold E. ;
Jones, Peter H. ;
McKenney, James M. ;
Grundy, Scott M. ;
Gill, Edward A. ;
Wild, Robert A. ;
Wilson, Don P. ;
Brown, W. Virgil .
JOURNAL OF CLINICAL LIPIDOLOGY, 2014, 8 (05) :473-488